PROTEOMICS FOR CLINICAL ASSESSMENT OF KIDNEY DISEASE

Thai Thanh Tam Tran1
1 Can Tho University of Medicine and Pharmacy

Main Article Content

Abstract

Kidney disease is one of the most common causes of death worldwide. Biomarkers have the potential to simplify the diagnosis and treatment of patients with various forms of kidney disease. Proteomic technologies have given renal physiologists and nephrologists broadened, powerful new tools for understanding normal and disease-related mechanisms in the kidney. The aim of this minireview is to provide an overview of the proteomic technologies currently applied to studies of kidney and highlight a few applications of such approaches in kidney disease biomarker discovery. 

Article Details

References

1. Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, Klein JB, Salant DJ (2009), M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy, N Engl J Med, 361, 11–21.
2. Bomback AS (2018), Management of membranous nephropathy in the PLA2R Era. Clin J Am Soc Nephrol,13, 784–786.
3. Chakraborty A, Sarwal M (2018), Protein biomarkers in renal transplantation, Expert Rev. Proteomics, 15, 41.
4. Couser WG (2017), Primary membranous nephropathy, Clin J Am Soc Nephrol, 12, 983–997.
5. Global Burden of Disease 2016 (2017), Causes of Death Collaborators, Lancet, 390,1151.
6. Good DM, Zu ̈rbig P, Argile ́s A, Bauer HW, Behrens G, Coon JJ, Dakna M,Decramer S, Delles C, Dominiczak AF, Ehrich JH, Eitner F, Fliser D, Frommberger M, Ganser A,
Girolami MA, Golovko I, Gwinner W, Haubitz M, Herget-Rosenthal S, Jankowski J, Jahn H, Jerums G, Julian BA, Kellmann M, Kliem V, Kolch W, Krolewski AS, Luppi M, Massy Z, Melter M, Neusu ̈ss C, Novak J, Peter K, Rossing K, Rupprecht H, Schanstra JP, Schiffer E, Stolzenburg JU, Tarnow L, Theodorescu D, Thongboonkerd V, Vanholder R, Weissinger EM, Mischak H, Schmitt-Kopplin P (2010), Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease, Mol Cell Proteomics, 9: 2424–2437.
7. Hoxha E, Thiele I, Zahner G, Panzer U, Harendza S, Stahl RA (2014), Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy, J Am Soc Nephrol, 25,1357–1366.
8. Liu P, Tseng G, Wang Z, Huang Y, Randhawa P (2019), Diagnosis of T-cell-mediated kidney rejection in formalin-fixed, paraffin-embedded tissues using RNA-Seq-based machine learning algorithms, Hum Pathol;84:283-290.
9. Niewczas MA, Gohda T, Skupien J, Smiles AM, Walker WH, Rosetti F, Cullere X, Eckfeldt JH, Doria A, Mayadas TN, Warram JH, Krolewski AS (2012), Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes, J Am Soc Nephrol, 23, 507–515.
10. Niewczas MA, Pavkov ME, Skupien J, Smiles A, Md Dom ZI, Wilson JM, Park J, Nair V, Schlafly A, Saulnier PJ, Satake E, Simeone CA, Shah H, Qiu C, Looker HC, Fiorina P, Ware CF, Sun JK, Doria A, Kretzler M, Susztak K, Duffin KL, Nelson RG, Krolewski AS (2019), A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes, Nat Med, 25, 805–813.